COMBACTE ASPIRE-ICU
Research type
Research Study
Full title
Advanced Understanding of Staphylococcus Aureus and Pseudomonas aeruginosa Infections in EuRopE - Intensive Care Units
IRAS ID
194137
Contact name
Matt Wise
Contact email
Sponsor organisation
University Medical Centre Utrecht
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 4 months, 30 days
Research summary
Hospitals are experiencing a growing problem of patients developing infections during their stay. These infections may lead to a deterioration in the condition on the patient and a longer stay in hospital. Patients who develop infections while in the intensive care unit, especially those patients that need help from a breathing machine, are of greater concern because of the severity of illness in this patient group.
Two serious infections that patients can develop during their stay in intensive care are infections in the lungs (pneumonia) and in the bloodstream. These are usually caused by bacteria. Unfortunately, it is often difficult for the intensive care doctors to identify those patients who are at greater risk of acquiring these infections and that would benefit from early preventative treatments.
For this reason, we will conduct an observational study that aims to help the ICU doctor in recognizing these patients that are at risk. We will collect basic medical information from those ICU patients on a breathing machine at ICU admission or within 24 hours, AND who have an expected stay in the ICU for at least 48 hours. Additionally we will collect extensive medical information and clinical samples from a smaller group of patients. We will follow the smaller group of patients that participate in this study during their ICU stay to assess whether they develop a pneumonia. With the results of this study we hope to identify the population at risk for developing these infections. This information helps development of future clinical trials that will investigate new preventive medication. ASPIRE-ICU is part of the European COMBACTE consortium and will take place in more than 30 sites across Europe.REC name
Wales REC 6
REC reference
16/WA/0243
Date of REC Opinion
19 Sep 2016
REC opinion
Further Information Favourable Opinion